LETTER TO EDITOR CODEN: AAJMBG

Plain abdominal radiography in zinc phosphide ingestion

Received: 24th May 2024; Accepted: 20th June 2024; Published: 01st July 2024

Dear Editor:

A 25-year-old woman presented to the hospital 7 to 8 hours after intentionally ingesting around 50 to 60 grams of zinc phosphide (ZnP). The patient's neurological examination was normal, but she had gastrointestinal complaints including nausea, vomiting, and mild epigastric pain. Her electrocardiogram was normal and her vital signs were stable. The results of her routine laboratory tests including coagulation profile, liver function tests, complete blood count, blood urea nitrogen (BUN), creatinine (Cr), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), blood sugar, sodium, potassium, magnesium, calcium, phosphate, and venous blood gas analyses were all within normal ranges.

The patients' pulse oximetry and cardiac monitoring were normal. Her plain abdominal radiography showed radiopaque materials in the pelvis and ascending colon (Figure 1).

Fig-1: Radiopaque materials in the pelvis and ascending colon



The patient was given 60 cc of oral castor oil every 6 hours until diarrhea occurred. Since the second day of hospital admission, the patient's liver transaminases have started to rise. Throughout her hospital stay, the peak levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 586 mg/dl and 1656 mg/dl, respectively.

The enzyme-linked immunosorbent assay (ELISA) results for anti-HCV and HIV antibodies and HBs surface antigen were all negative. The patient's liver ultrasound showed abnormalities. Silymarin (Livergol®) was started at a dosage of 140 mg orally every 6 hours. Due to the increase in AST and ALT levels, intravenous Nacetylcysteine (NAC) was initiated with a loading dose of 150 mg/kg over 4 hours followed by 300 mg/kg/day. Since the seventh day, the patient's AST and ALT levels have started to decrease. On the eleventh day, she was discharged with a prescription for Livergol® at a dosage of 140 mg orally every 12 hours. She was also scheduled for a followup appointment in the next two days.

Zinc phosphide is a rodenticide and its lethal dose for humans is close to 50 to 500 mg/kg. Usually, 30 to 60 percent of patients who have ingested ZnP are asymptomatic [1]. The clinical manifestations of ZnP poisoning usually appear a few days after ingestion. An asymptomatic patient should be hospitalized and monitored for 3 to 4 days [1]. Common symptoms of ZnP poisoning include nausea, abdominal vomiting, pain, confusion, diarrhea, depressed level of consciousness, headache, agitation, chest pain, weakness, dyspnea, and acute kidney injury.

treatment is

Other rare manifestations may include tachypnea, hyperpnea, coughing, sweating, tachycardia, hypotension, electrocardiographic abnormalities, various dysrhythmias, seizures, acute respiratory distress syndrome, hemolysis, disseminated intravascular coagulation, pancreatitis, and liver failure. Some laboratory abnormalities such as metabolic acidosis, hypo- and hyperglycemia, hypo and hyperkalemia, hypo- and hypernatremia, coagulation disorders, an increase in liver transaminases (AST and ALT), an increase in BUN, Cr, LDH, and CPK levels have also been reported [1-4].

A study has shown that if plain abdominal radiography is negative, 90% of patients will remain asymptomatic. In contrast, if the radiography is positive, there is a high possibility of acidosis, increased liver transaminases, and kidney failure [5]. There is no antidote for ZnP

symptomatic therapy. Despite controversy, it is recommended to administer oral polyethylene glycol or castor oil if abdominal radiography shows radiopaque materials. Treatment with sodium bicarbonate, calcium gluconate, antidysrhythmics, magnesium sulfate, hydrocortisone, NAC, vitamin E, pantoprazole, and tranexamic acid is also recommended [1-5].

poisoning, so the main

Acknowledgments

The author would like to thank EditMyEnglish (https://www.editmyenglish.com/freeediting.aspx) for editing the English language. The patient has provided written informed consent for the publication of this report. This case was approved for reporting by the Committee of Ethics in Research at the Medical School of Shiraz University of Medical Sciences and has been registered as IR.SUMS.MED.REC.1403.132.

Financial Support and sponsorship: Nil

Conflicts of interest: There are no conflicts of interest.

References

- El Naggar ARM, El Mahdy NM. Zinc phosphide toxicity with a trial of tranexamic acid in its management. J Adv Res. 2011; 2:149-156.
- Chugh SN, Aggarwal HK, Mahajan SK. Zinc phosphide intoxication symptoms: analysis of 20 cases. *Int J Clin Pharmacol Ther*. 1998; 36(7):406-407.
- 3. Frangides CY, Pneumatikos IA. Persistent severe hypoglycemia in acute zinc phosphide poisoning. *Intensive Care Med.* 2002; 28(2):223.
- 4. Jain J, Jain VV, Gupta OP et al. A Transient hyperglycemia in zinc phosphide poisoning. *Indian J Endocrinol Metab.* 2012; 16(1):145-146.
- 5. Hassanian-Moghaddam H, Shahnazi M, Zamani N et al. Plain abdominal radiography: a powerful tool to

prognosticate outcome in patients with zinc phosphide poisoning. *Clin Radiol.* 2014; 69(10):1062-1065.

Cite this article as: Sanaei-Zadeh H. Plain abdominal radiography in zinc phosphide ingestion. *Al Ameen J Med Sci* 2024; 17(3): 269-270.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial (CC BY-NC 4.0) License, which allows others to remix, adapt and build upon this work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms

Hossein Sanaei-Zadeh*

Emergency Room, Division of Medical Toxicology, Hazrat Ali-Asghar (p) Hospital, Meshkinfam Street 7143918796, Department of Emergency Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

*All correspondences to: Dr. Hossein Sanaei-Zadeh, MD, Emergency Room, Division of Medical Toxicology, Hazrat Ali-Asghar (p) Hospital, Meshkinfam Street 7143918796, Department of Emergency Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail: sanaeizadeh@sums.ac.ir